SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.
Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to ...
In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.
18hon MSN
A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...
New Delhi: Mylan Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...
Dr. Ayo presents his final in the series of Heart and Stroke month preventative care tips in Part 6 during Heart and Stroke awareness ...
5d
HealthDay on MSNWhat Is Cardiovascular Disease?Cardiovascular disease is a general term that refers to many different types of heart problems.Heart disease is the ...
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 millionCash resources and cash ...
Valcare Medical Inc., a leading innovator in transcatheter-based mitral solutions, today announced the U.S. Food and Drug ...
13h
Medpage Today on MSNRapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 InhibitorORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing ...
Medtronic (NYSE: MDT) announced results from a registry highlighting the effectiveness of the Prevail drug-coated balloon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results